Impact of alemtuzumab therapy and route of administration in T-prolymphocytic leukemia: A single-center experience

Moussab Damlaj, Nanna H. Sulai, Jennifer L. Oliveira, Rhett P. Ketterling, Shahrukh Hashmi, Thomas Witzig, Grzegorz Nowakowski, Timothy G. Call, Tait D. Shanafelt, Wei Ding, William J. Hogan, Mark R. Litzow, Mrinal M. Patnaik

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Objective We conducted a single-center retrospective analysis to determine the impact of the anti-CD52 monoclonal antibody alemtuzumab including route of administration compared to non-alemtuzumab-containing regimens in T-prolymphocytic leukemia (T-PLL). Patients and Methods The study was a retrospective analysis of a consecutive cohort of adult patients diagnosed with T-PLL at Mayo Clinic Rochester from January 1, 1997, through September 30, 2014. Results A total of 41 patients were diagnosed with T-PLL per the World Health Organization 2008 classification. The median age was 66 years, and 23 (56%) were male. After a median follow-up of 18 months (range, 0.4-66.1 months), 32 patients (78%) had died, with a median overall survival of 16.9 months. Approximately half the cohort was treated with alemtuzumab, almost exclusively after 2004. Median survival for patients receiving intravenous alemtuzumab-based therapy was 40.5 versus 10.3 months for all other therapies (P =.0004). A significant survival difference between intravenous versus subcutaneous alemtuzumab administration of 40.5 versus 13.7 months was noted (P =.0014). Only 4 (14%) of 28 patients aged < 70 years underwent hematopoietic stem cell transplantation, with a median survival after transplantation of 4 months. Conclusion In this large series of T-PLL patients treated at a single tertiary-care center, we confirmed the prior observation of the superiority of intravenous alemtuzumab over other therapies. Hematopoietic stem cell transplantation was feasible in a minority of potentially eligible patients. Early transplant referral should be considered for all eligible patients.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number11
StatePublished - Nov 2015


  • Alemtuzumab
  • GVHD
  • HSCT
  • T-PLL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Impact of alemtuzumab therapy and route of administration in T-prolymphocytic leukemia: A single-center experience'. Together they form a unique fingerprint.

Cite this